Vericiguat
As of the edition of 20 October 2026, Vericiguat is a small molecule: marketed, first approved in 2021 (US); acts on GUCY1A1, GUCY1A2 and GUCY1B1 and 1 more; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Verquvo
- First approved
- 19 January 2021 (US)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- Bayer; 3 holders in all
- Registered trials
- 39, 0 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Cancer; Lungs and airways; Mental health; Skin and connective tissue
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Vericiguat.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 5 | 7 | 0 |
| Phase 1 | 8 | 7 | 1 | 0 |
| Phase 2 | 9 | 6 | 3 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| Phase 4 | 7 | 2 | 5 | 0 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant and Lead sponsor of trials | 2013 to now |
| Merck & Co. | Originator and Lead sponsor of trials | 2016 to now |